The evolving classification of soft tissue tumours - an update based on the new 2013 WHO classification

Histopathology

Volumn 64, Issue 1, 2014, Pages 2-11

  Fletcher, Christopher D M ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Sarcoma; Soft tissue; Tumour; WHO

Indexed keywords

B RAF KINASE; MYC PROTEIN; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; STAT6 PROTEIN; SUCCINATE DEHYDROGENASE; TUBERIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADIPOCYTE; ANGIOSARCOMA; CARNEY COMPLEX; CELL STRUCTURE; CHONDROSARCOMA; DERMATOFIBROSARCOMA PROTUBERANS; EMBRYONAL RHABDOMYOSARCOMA; FIBROBLAST; FIBROSARCOMA; FUSION GENE; GASTROINTESTINAL STROMAL TUMOR; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; HEMANGIOENDOTHELIOMA; HUMAN; LEIOMYOMA; MALIGNANT FIBROUS HISTIOCYTOMA; MOLECULAR GENETICS; MUSCLE TUMOR; MYOEPITHELIOMA; MYOFIBROBLAST; MYXOSARCOMA; NERVE SHEATH TUMOR; NEUROFIBROMA; PERICYTE; PERIVASCULAR EPITHELIOID CELL TUMOR; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SOFT TISSUE TUMOR; SOLITARY FIBROUS TUMOR; SPINDLE CELL; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; VASCULAR TUMOR; WORLD HEALTH ORGANIZATION;

SARCOMA; SOFT TISSUE; TUMOUR; WHO;

HUMANS; SOFT TISSUE NEOPLASMS; WORLD HEALTH ORGANIZATION;

EID: 84889658911     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12267     Document Type: Review

References (56)

1. Fletcher CDM, Unni KK, Mertens F eds. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press, 2002.
2. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F eds. World Health Organization classification of tumours of soft tissue and bone, 4th edn. Lyon: IARC Press, 2013.
3. Erickson-Johnson MR, Chou MM, Evers BR et al. Nodular fasciitis: a novel model of transient neoplasia induced by MYH9-USP6 gene fusion. Lab. Invest. 2011; 91; 1427-1433.
4. Oliveira AM, Hsi BL, Weremowicz S et al. USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Res. 2004; 64; 1920-1923.
5. Guillou L, Benhattar J, Gengler C et al. Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group. Am. J. Surg. Pathol. 2007; 31; 1387-1402.
6. Doyle LA, Wang WL, Dal Cin P et al. MUC4 is a sensitive and extremely useful marker for sclerosing epithelioid fibrosarcoma: association with FUS gene rearrangement. Am. J. Surg. Pathol. 2012; 36; 1444-1451.
7. Wang WL, Evans HL, Meis JM et al. FUS rearrangements are rare in 'pure' sclerosing epithelioid fibrosarcoma. Mod. Pathol. 2012; 25; 846-853.
8. Chakrapani A, Warrick A, Nelson D et al. BRAF and KRAS mutations in sporadic glomus tumours. Am. J. Dermatopathol. 2012; 34; 533-535.
9. Brems H, Park C, Maertens O et al. Glomus tumours in neurofibromatosis type 1: genetic, functional and clinical evidence of a novel association. Cancer Res. 2009; 69; 7393-7401.
10. Mosquera JM, Sboner A, Zhang L et al. Novel MIR143-NOTCH fusions in benign and malignant glomus tumours. Genes Chromosom. Cancer 2013; 52; 1075-1087.
11. Mosquera JM, Sboner A, Zhang L et al. Recurrent NCOA2 gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosom. Cancer 2013; 52; 538-550.
12. Hornick JL, Fletcher CD. Pseudomyogenic hemangioendothelioma: a distinctive, often multicentric tumour with indolent behavior. Am. J. Surg. Pathol. 2011; 35; 190-201.
13. Billings SD, Folpe AL, Weiss SW. Epithelioid sarcoma-like hemangioendothelioma. Am. J. Surg. Pathol. 2003; 27; 48-57.
14. Trombetta D, Magnusson L, von Steyern FV et al. Translocation t(7;19)(q22;q13) - a recurrent chromosome aberration in pseudomyogenic hemangioendothelioma? Cancer Genet. 2011; 204; 211-215.
15. Demetri GD, von Mehren M, Antonescu CR et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumours. J. Natl Compr. Canc. Netw. 2010; 8(Suppl. 2); S1-S41.
16. Gill AJ, Chou A, Vilain R et al. Immunohistochemistry for SDHB divides gastrointestinal stromal tumours (GISTs) into 2 distinct types. Am. J. Surg. Pathol. 2010; 34; 636-644.
17. Janeway KA, Kim SY, Lodish M et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumours lacking KIT and PDGFRA mutations. Proc. Natl Acad. Sci. USA 2011; 108; 314-318.
18. Miettinen M, Wang ZF, Sarlomo-Rikala M et al. Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical and molecular genetic study of 66 gastric GISTs with predilection to young age. Am. J. Surg. Pathol. 2011; 35; 1712-1721.
19. Wagner AJ, Remillard SP, Zhang YX et al. Loss of expression of SDHA predicts SDHA mutations in gastrointestinal stromal tumours. Mod. Pathol. 2013; 26; 289-294.
20. Dwight T, Benn DE, Clarkson A et al. Loss of SDHA expression identifies SDHA mutations in succinate dehydrogenase-deficient gastrointestinal stromal tumours. Am. J. Surg. Pathol. 2013; 37; 226-233.
21. Hornick JL, Bundock EA, Fletcher CD. Hybrid schwannoma/perineurioma: clinicopathologic analysis of 42 distinctive benign nerve sheath tumours. Am. J. Surg. Pathol. 2009; 33; 1554-1561.
22. Feany MB, Anthony DC, Fletcher CD. Nerve sheath tumours with hybrid features of neurofibroma and schwannoma: a conceptual challenge. Histopathology 1998; 32; 405-410.
23. Harder A, Wesemann M, Hagel C et al. Hybrid neurofibroma/schwannoma is overrepresented among schwannomatosis and neurofibromatosis patients. Am. J. Surg. Pathol. 2012; 36; 702-709.
24. Fetsch JF, Laskin WB, Miettinen M. Superficial acral fibromyxoma: a clinicopathologic and immunohistochemical analysis of 37 cases of a distinctive soft tissue tumour with a predilection for the fingers and toes. Hum. Pathol. 2001; 32; 704-714.
25. Hollmann TJ, Bovée JV, Fletcher CD. Digital fibromyxoma (superficial acral fibromyxoma): a detailed characterization of 124 cases. Am. J. Surg. Pathol. 2012; 36; 789-798.
26. Marshall-Taylor C, Fanburg-Smith JC. Hemosiderotic fibrohistiocytic lipomatous lesion: ten cases of a previously undescribed fatty lesion of the foot/ankle. Mod. Pathol. 2000; 13; 1192-1199.
27. Browne TJ, Fletcher CD. Haemosiderotic fibrolipomatous tumour (so-called haemosiderotic fibrohistiocytic lipomatous tumour): analysis of 13 new cases in support of a distinct entity. Histopathology 2006; 48; 453-461.
28. Hallor KH, Sciot R, Staaf J et al. Two genetic pathways, t(1;10) and amplification of 3p11-12 in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour and morphologically similar lesions. J. Pathol. 2009; 217; 716-727.
29. Antonescu CR, Zhang L, Nielsen GP et al. Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumour. Genes Chromosom. Cancer 2011; 50; 757-764.
30. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumours. A polymorphous group causing osteomalacia or rickets. Cancer 1987; 59; 1442-1454.
31. Folpe AL, Fanburg-Smith JC, Billings SD et al. Most osteomalacia-associated mesenchymal tumours are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am. J. Surg. Pathol. 2004; 28; 1-30.
32. Bahrami A, Weiss SW, Montgomery E et al. RT-PCR analysis for FGF23 using paraffin sections in the diagnosis of phosphaturic mesenchymal tumours with and without known tumour-induced osteomalacia. Am. J. Surg. Pathol. 2009; 33; 1348-1354.
33. Fletcher CD. Undifferentiated sarcomas: what to do? And does it matter? A surgical pathology perspective Ultrastruct. Pathol. 2008; 32; 31-36.
34. Sakharpe A, Lahat G, Gulamhusein T et al. Epithelioid sarcoma and unclassified sarcoma with epithelioid features: clinicopathological variables, molecular markers and a new experimental model. Oncologist 2011; 16; 512-522.
35. Italiano A, Sung YS, Zhang L et al. High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. Genes Chromosom. Cancer 2012; 51; 207-218.
36. Graham C, Chilton-MacNeill S, Zielenska M, Somers GR. The CIC-DUX4 fusion transcript is present in a subgroup of pediatric primitive round cell sarcomas. Hum. Pathol. 2012; 43; 180-189.
37. Robinson DR, Wu YM, Kalyana-Sundaram S et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumour by integrative sequencing. Nat. Genet. 2013; 45; 180-185.
38. Chmielecki J, Crago AM, Rosenberg M et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumours. Nat. Genet. 2013; 45; 131-132.
39. Schweizer L, Koelsche C, Sahm F et al. Meningeal hemangiopericytoma and solitary fibrous tumours carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 2013; 125; 651-658.
40. Doyle LA, Vivero M, Fletcher CD, Mertens F, Hornick JL. Nuclear expression of STAT6 distinguishes solitary fibrous tumour from histologic mimics. Mod. Pathol. 2013; (in press).
41. Antonescu CR, Dal Cin P, Nafa K et al. EWSR1-CREB1 is the predominant gene fusion in angiomatoid fibrous histiocytoma. Genes Chromosom. Cancer 2007; 46; 1051-1060.
42. Rossi S, Szuhai K, Ijszenga M et al. EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma. Clin. Cancer Res. 2007; 13; 7322-7328.
43. Mertens F, Fletcher CD, Antonescu CR et al. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma and cloning of a novel FUS/CREB3L1 fusion gene. Lab. Invest. 2005; 85; 408-415.
44. Antonescu CR, Zhang L, Chang NE et al. EWSR1-POU5F1 fusion in soft tissue myoepithelial tumours. A molecular analysis of sixty-six cases, including soft tissue, bone and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosom. Cancer 2010; 49; 1114-1124.
45. Errani C, Zhang L, Sung YS et al. A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosom. Cancer 2011; 50; 644-653.
46. Tanas MR, Sboner A, Oliveira AM et al. Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci. Transl. Med. 2011; 3; 98ra82.
47. Wang L, Motoi T, Khanin R et al. Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosom. Cancer 2012; 51; 127-139.
48. Gebre-Medhin S, Nord KH, Möller E et al. Recurrent rearrangement of the PHF1 gene in ossifying fibromyxoid tumours. Am. J. Pathol. 2012; 181; 1069-1077.
49. Pan CC, Chung MY, Ng KF et al. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma. J. Pathol. 2008; 214; 387-393.
50. Folpe AL, Kwiatkowski DJ. Perivascular epithelioid cell neoplasms: pathology and pathogenesis. Hum. Pathol. 2010; 41; 1-15.
51. Argani P, Aulmann S, Illei PB et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am. J. Surg. Pathol. 2010; 34; 1395-1406.
52. Malinowska I, Kwiatkowski DJ, Weiss S. Perivascular epithelioid cell tumours (PEComas) harboring TFE3 gene rearrangements lack the TSC2 alterations characteristic of conventional PEComas: further evidence for a biological distinction. Am. J. Surg. Pathol. 2012; 36; 783-784.
53. Antonescu CR, Yoshida A, Guo T et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res. 2009; 69; 7175-7179.
54. Manner J, Radlwimmer B, Hohenberger P et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am. J. Pathol. 2010; 176; 34-39.
55. Guo T, Zhang L, Chang NE. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions. Genes Chromosom. Cancer 2011; 50; 25-33.
56. Italiano A, Thomas R, Breen M et al. The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. Genes Chromosom. Cancer 2012; 51; 569-578.